Intercept Pharmaceuticals (NASDAQ:ICPT) Downgraded by BidaskClub

BidaskClub downgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a hold rating to a sell rating in a research report released on Thursday, BidAskClub reports.

A number of other research analysts also recently commented on ICPT. Citigroup upgraded Intercept Pharmaceuticals from a neutral rating to a buy rating and lowered their price objective for the stock from $106.00 to $85.00 in a research note on Wednesday, September 4th. Oppenheimer lowered their price objective on Intercept Pharmaceuticals from $170.00 to $160.00 and set an outperform rating for the company in a research note on Tuesday, August 6th. Wedbush set a $243.00 price objective on Intercept Pharmaceuticals and gave the stock a buy rating in a research note on Monday, September 30th. Stifel Nicolaus restated a hold rating and set a $86.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday, August 12th. Finally, Raymond James set a $148.00 price objective on Intercept Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 23rd. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $132.90.

ICPT traded up $1.28 during trading on Thursday, reaching $60.83. 369,929 shares of the company were exchanged, compared to its average volume of 769,046. The stock has a market cap of $1.93 billion, a P/E ratio of -5.60 and a beta of 1.16. The firm has a 50 day moving average of $64.48 and a 200 day moving average of $78.41. The company has a current ratio of 6.54, a quick ratio of 6.54 and a debt-to-equity ratio of 3.11. Intercept Pharmaceuticals has a 52 week low of $56.76 and a 52 week high of $131.87.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($2.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.51) by $0.23. The firm had revenue of $66.30 million during the quarter, compared to the consensus estimate of $58.78 million. Intercept Pharmaceuticals had a negative return on equity of 534.42% and a negative net margin of 143.57%. The firm’s revenue was up 52.2% on a year-over-year basis. During the same period in the prior year, the business earned ($2.58) EPS. As a group, analysts forecast that Intercept Pharmaceuticals will post -9.85 earnings per share for the current fiscal year.

In related news, insider David A. Ford sold 800 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $56,000.00. Following the completion of the transaction, the insider now owns 11,546 shares of the company’s stock, valued at $808,220. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Srinivas Akkaraju bought 5,207 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were purchased at an average cost of $60.32 per share, with a total value of $314,086.24. Following the purchase, the director now directly owns 21,526 shares of the company’s stock, valued at $1,298,448.32. The disclosure for this purchase can be found here. Corporate insiders own 5.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC boosted its stake in Intercept Pharmaceuticals by 2,916.7% during the third quarter. Larson Financial Group LLC now owns 543 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 525 shares in the last quarter. AdvisorNet Financial Inc bought a new position in Intercept Pharmaceuticals during the second quarter valued at about $56,000. Compagnie Lombard Odier SCmA bought a new position in Intercept Pharmaceuticals during the second quarter valued at about $80,000. NumerixS Investment Technologies Inc bought a new position in Intercept Pharmaceuticals during the second quarter valued at about $88,000. Finally, Coastal Investment Advisors Inc. boosted its stake in Intercept Pharmaceuticals by 124.9% during the second quarter. Coastal Investment Advisors Inc. now owns 1,417 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 787 shares in the last quarter. 80.96% of the stock is owned by institutional investors and hedge funds.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Recommended Story: What is a Lock-Up Period?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.